Volume 12 Supplement 2

Advanced breast cancer therapy

Reviews

Edited by Jenny Chang

Publication of this supplement has been sponsored by Bristol Myers Squibb Company. Translation services and administrative support was provided to the authors by Thomson Reuters, Healthcare and Science.

Present and future evolution of advanced breast cancer therapy

Although the introduction of novel therapies and drug combinations has improved the prognosis of metastatic breast cancer, the disease remains incurable. Increased knowledge of the biology and the molecular al...

Authors: Ricardo H Álvarez

Citation: Breast Cancer Research 2010 12(Suppl 2):S1

Content type: Review Published on: 22 October 2010
- View Full Text
- View PDF
Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone

Resistance to chemotherapy is a major obstacle to the effective treatment of many tumor types. Although many anticancer therapies can alter tumor growth, in most cases the effect is not long lasting. Consequen...

Authors: Edgardo Rivera and Henry Gomez

Citation: Breast Cancer Research 2010 12(Suppl 2):S2

Content type: Proceedings Published on: 22 October 2010
- View Full Text
- View PDF
Triple-negative breast cancer

Perou's molecular classification defines tumors that neither express hormone receptors nor overexpress HER2 as triple-negative (TN) tumors. These tumors account for approximately 15% of breast cancers. The so-...

Authors: Reinaldo D Chacón and María V Costanzo

Citation: Breast Cancer Research 2010 12(Suppl 2):S3

Content type: Review Published on: 22 October 2010
- View Full Text
- View PDF

Advanced breast cancer therapy

Reviews

Present and future evolution of advanced breast cancer therapy

Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone

Triple-negative breast cancer

Follow

Annual Journal Metrics

Breast Cancer Research

Contact us